Auto-generated from public data. Not the firm's stated position.
Integra Holdings appears to focus on early-stage biotech investments, particularly in therapeutic modalities including immuno-oncology, genetic treatments, and advanced medical devices. Recent portfolio suggests a preference for companies addressing unmet needs in oncology and rare genetic diseases, with check sizes typically ranging from €0.1M to €1.5M at pre-seed and seed stages.
Generated 1 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-extracted from press releases.
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.